Sarepta Therapeutics Inc (SRPT)

09:21 AM

Sarepta Therapeutics (NASDAQ:SRPT) COO Ian Michael Estepan Sells 13,187 Shares - MarketBeat

09:21 AM

03:51 AM

Why analysts raise outlook for Sarepta Therapeutics Inc. (AB3A) stock2025 Trading Recap & Long-Term Capital Growth Strategies - Улправда

03:51 AM

01:23 AM

Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory - Insider Monkey

01:23 AM

01:13 AM

Viking Therapeutics, Inc. (VKTX): A Bull Case Theory - Yahoo Finance

01:13 AM

06:26 AM

Will Sarepta Therapeutics Inc. stock maintain momentum in 2025Exit Point & Technical Buy Zone Confirmations - Улправда

06:26 AM

Dec 17, 2025

Sarepta Therapeutics Inc Stock Analysis and ForecastRisk-Reward Ratio Analysis & Low Entry Investment Portfolio - earlytimes.in

Dec 17, 2025

Dec 17, 2025

Precision Trading with Sarepta Therapeutics Inc. (SRPT) Risk Zones - news.stocktradersdaily.com

Dec 17, 2025

Dec 17, 2025

Sarepta Therapeutics, Inc. (SRPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Dec 17, 2025

Dec 17, 2025

Sarepta Therapeutics Applauds Addition of Duchenne Muscular Dystrophy to the U.S. Recommended Uniform Screening Panel (RUSP) - Sarepta Therapeutics

Dec 17, 2025

Dec 17, 2025

Sarepta Therapeutics: Why The Newborn Screening Decision For DMD Matters More Than The Stock Move Suggests - Seeking Alpha

Dec 17, 2025

Dec 17, 2025

Analysts Offer Insights on Healthcare Companies: Elevance Health (ELV), Argenx Se (ARGX) and Sarepta Therapeutics (SRPT) - The Globe and Mail

Dec 17, 2025

Dec 17, 2025

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Recommendation of "Hold" by Brokerages - MarketBeat

Dec 17, 2025

Dec 16, 2025

Sarepta Therapeutics (NASDAQ:SRPT) Shares Up 5.3%Still a Buy? - MarketBeat

Dec 16, 2025

Dec 16, 2025

Sarepta Therapeutics (SRPT) Stock: Latest News, Analyst Forecasts, and Key Catalysts to Watch on Dec. 16, 2025 - ts2.tech

Dec 16, 2025

Dec 16, 2025

Why Sarepta Therapeutics Stock is Gaining Attention - TipRanks

Dec 16, 2025

Dec 16, 2025

Sarepta Therapeutics (SRPT) Rises as HHS Expands Newborn Screeni - GuruFocus

Dec 16, 2025

Dec 16, 2025

Sarepta rises as HHS adds Duchenne muscular dystrophy to newborn screenings - Seeking Alpha

Dec 16, 2025

Dec 14, 2025

A mom was overjoyed when she learned a drug could save her baby's life. Then she learned it cost $2 million. - CBS News

Dec 14, 2025

Dec 13, 2025

683 Capital Management LLC Grows Stock Position in Sarepta Therapeutics, Inc. $SRPT - MarketBeat

Dec 13, 2025

Dec 12, 2025

Sarepta Therapeutics (NASDAQ:SRPT) Shares Gap DownHere's What Happened - MarketBeat

Dec 12, 2025

Dec 12, 2025

Sarepta Therapeutics Refinances Convertible Senior Notes - The Globe and Mail

Dec 12, 2025

Dec 12, 2025

Sarepta CEO given first equity award in 8 years - The Business Journals

Dec 12, 2025

Dec 12, 2025

Arrowhead Pharma secures $200M milestone from Sarepta Therapeutics - MSN

Dec 12, 2025

Dec 12, 2025

Sarepta Therapeutics refinances convertible senior notes - MSN

Dec 12, 2025

Dec 11, 2025

Mizuho reiterates Outperform rating on Sarepta stock amid debt refinancing - Investing.com

Dec 11, 2025

Dec 11, 2025

Mizuho reiterates Outperform rating on Sarepta stock amid debt refinancing By Investing.com - Investing.com UK

Dec 11, 2025

Dec 11, 2025

Sarepta Therapeutics stock falls after debt exchange announcement By Investing.com - Investing.com South Africa

Dec 11, 2025

Dec 11, 2025

Sarepta Therapeutics stock falls after debt exchange announcement - Investing.com

Dec 11, 2025

Dec 11, 2025

Why Is SRPT Stock Falling Today? - Stocktwits

Dec 11, 2025

Dec 11, 2025

Sector Update: Health Care Stocks Mixed Premarket Thursday - marketscreener.com

Dec 11, 2025

Dec 11, 2025

Sarepta dips after announcing debt refinancing - TradingView

Dec 11, 2025

Dec 11, 2025

Sarepta Therapeutics stock falls after refinancing of convertible notes By Investing.com - Investing.com South Africa

Dec 11, 2025

Dec 11, 2025

Sarepta Therapeutics stock falls after refinancing of convertible notes - Investing.com

Dec 11, 2025

Dec 11, 2025

Sarepta to refinance $291M of existing notes due 2027 - MSN

Dec 11, 2025

Dec 11, 2025

Sarepta Therapeutics Refinances $291 Million in Convertible Senior Notes Due 2027 - marketscreener.com

Dec 11, 2025

Dec 11, 2025

Sarepta Therapeutics announces refinancing of approximately $291 million of 1.25% convertible senior notes due 2027 - marketscreener.com

Dec 11, 2025

Dec 11, 2025

Sarepta Therapeutics Announces Refinancing Of Approximately $291 Million Of 1.25% Convertible Senior Notes Due 2027 - TradingView — Track All Markets

Dec 11, 2025

Dec 11, 2025

Sarepta to exchange $291.4 million in convertible notes - Investing.com

Dec 11, 2025

Dec 11, 2025

Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027 - Business Wire

Dec 11, 2025

Dec 10, 2025

CFO Wong Surrenders 158 Of Sarepta Therapeutics Inc [SRPT] - TradingView — Track All Markets

Dec 10, 2025

Dec 10, 2025

Sarepta Therapeutics' Myotonic Dystrophy Type 1 Trial Data Could Boost Investor Sentiment, Oppenheimer Says - marketscreener.com

Dec 10, 2025

Dec 10, 2025

United States Gene Therapy Market to Hit $6510.45 Million by 2033 - openPR.com

Dec 10, 2025

Dec 10, 2025

Sarepta Therapeutics, Inc. $SRPT Shares Bought by Federated Hermes Inc. - MarketBeat

Dec 10, 2025

Dec 10, 2025

Sarepta Therapeutics (NASDAQ:SRPT) Nasdaq Index Tracks Biotech Advancements - Kalkine Media

Dec 10, 2025

Dec 10, 2025

Sarepta Therapeutics (SRPT): Reassessing Valuation After a Sharp One-Month Share Price Rebound - Yahoo Finance

Dec 10, 2025

Dec 09, 2025

Is Sarepta Therapeutics a Bargain After Recent Share Rebound and DCF Valuation Check? - Yahoo Finance

Dec 09, 2025

Dec 09, 2025

Sarepta Therapeutics Gets A Vote Of Confidence After Sell-Off - Finimize

Dec 09, 2025

Dec 09, 2025

Wedbush Says Sarepta Selloff “Overdone” - GuruFocus

Dec 09, 2025

Dec 09, 2025

Sarepta Therapeutics (NASDAQ:SRPT) Shares Gap UpWhat's Next? - MarketBeat

Dec 09, 2025

Dec 09, 2025

Sarepta Offers 'Attractive' Entry Point After Setbacks, Wedbush Says - marketscreener.com

Dec 09, 2025

Dec 09, 2025

Sarepta Therapeutics (SRPT) Rated Outperform by Wedbush with 46% Upside Potential - GuruFocus

Dec 09, 2025

Dec 09, 2025

Sarepta a new outperform at Wedbush as selloff overdone - Seeking Alpha

Dec 09, 2025

Dec 09, 2025

Sarepta Therapeutics (NASDAQ:SRPT) Coverage Initiated by Analysts at Wedbush - MarketBeat

Dec 09, 2025

Dec 09, 2025

SRPT: Wedbush Initiates Coverage with Outperform Rating | SRPT S - GuruFocus

Dec 09, 2025

Dec 09, 2025

Wedbush initiates Sarepta Therapeutics stock coverage with Outperform rating - Investing.com

Dec 09, 2025

Dec 09, 2025

Wedbush initiates Sarepta Therapeutics stock coverage with Outperform rating By Investing.com - Investing.com UK

Dec 09, 2025

Dec 09, 2025

Sarepta (SRPT) Stock Outlook: Wedbush Predicts Potential Growth - GuruFocus

Dec 09, 2025

Dec 09, 2025

Regenerative Medicine Market 2025-2033: Key Trends, Research - openPR.com

Dec 09, 2025

Dec 09, 2025

New York State Common Retirement Fund Sells 7,923,000 Shares of Sarepta Therapeutics, Inc. $SRPT - MarketBeat

Dec 09, 2025

Dec 09, 2025

Norges Bank Buys Shares of 913,407 Sarepta Therapeutics, Inc. $SRPT - MarketBeat

Dec 09, 2025

Dec 09, 2025

Sarepta Therapeutics (SRPT) Is Up 6.8% After FDA Clears Cohort 8 Dosing in ENDEAVOR Trial - simplywall.st

Dec 09, 2025

Dec 08, 2025

Dyne Readies DMD Exon-Skipper For Filing, Could Be Competitive With Sarepta Drug - Citeline News & Insights

Dec 08, 2025

Dec 08, 2025

Sarepta Therapeutics grants $12 million equity award to CEO Douglas Ingram - Investing.com Nigeria

Dec 08, 2025

Dec 08, 2025

Why Is Dyne Therapeutics Stock Surging Monday?Dyne Therapeutics (NASDAQ:DYN), Sarepta Therapeutics (NASDAQ:SRPT) - Benzinga

Dec 08, 2025